Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing ‘next-generation cell therapeutics’ - Signs strategic platform licence with Wugen Inc, a US-based clinical-stage biotech company developing off-the-shelf cell therapies for the treatment of hematological and solid cancer tumour malignancies. Wugen’s lead program is evaluating WU-CART-007, a cell therapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukaemia. Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte’s unique Flow electroporation technology and its trademarked ExPERT research platform. In exchange, MaxCyte will receive annual licence fees and programme-related revenue, although precise transaction details were not provided.
Commenting on the deal, MaxCyte Chief Executive Officer Maher Masoud said: ‘As WU-CART-007 is transferred onto the ExPERT platform and continues to progress in the clinic, we are able to support efficient and seamless expansion to large-scale manufacturing.
‘By working with MaxCyte, Wugen can maximize the number of doses in each manufacturing run for later stage clinical development and potential commercial phase.’
Current stock price: 385.00 pence each, down 3.1% in London on Tuesday afternoon.
12-month change: down 16%
Copyright 2024 Alliance News Ltd. All Rights Reserved.